UBS Group’s Ascentage Pharma AAPG Stock Holding History

UBS Group’s Portfolio AAPG Stock Details AAPG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$263	Sell	15 -109	-88%	-$2.32K	﹤0.01%	9958
2026 Q1	$2.96K	Sell	124 -4,108	-97%	-$101K	﹤0.01%	9169
2025 Q4	$111K	Sell	4,232 -14,113	-77%	-$462K	﹤0.01%	6862
2025 Q3	$716K	Buy	18,345 +10,988	+149%	+$445K	﹤0.01%	5827
2025 Q2	$290K	Buy	7,357 +4,879	+197%	+$129K	﹤0.01%	6463
2025 Q1	$54.4K	Buy	+2,478	New	+$47K	﹤0.01%	7528

Other funds holding AAPG

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

UBS Group's AAPG Position: Q2 2026 in Review

UBS Group reduced its Ascentage Pharma (AAPG) stake by 88% in Q2 2026, selling an estimated $2.32K and leaving 15 shares worth $263. The position accounts for ﹤0.01% of the portfolio, ranked #9958.

UBS Group first reported a position in AAPG in Q1 2025 and has held it in 6 quarters since. The position peaked at $716K in Q3 2025. 8 funds tracked by Wall St. Rank hold AAPG as of Q2 2026.

UBS Group held 15 shares of Ascentage Pharma worth $263 as of Q2 2026.
UBS Group sold 109 Ascentage Pharma shares in Q2 2026, an estimated $2.32K.
Ascentage Pharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9958 holding.
UBS Group first reported a position in Ascentage Pharma in Q1 2025 and has held it in 6 quarters since.
UBS Group's Ascentage Pharma position peaked at $716K in Q3 2025.
8 funds tracked by Wall St. Rank held Ascentage Pharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.